Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview

American Journal of Health-System Pharmacy

Volumn 64, Issue 13 SUPPL., 2007, Pages

  Dowling, Thomas C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Anemia; Classification; Costs; Drug administration routes; Economics; Epidemiology; Epoetin alfa; Hematopoietic agents; Injections; Kidney diseases; Mortality; Quality of life

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANGINA PECTORIS; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONFERENCE PAPER; DIALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FUNCTION; HEMATOCRIT; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED STATES; WORK CAPACITY;

EID: 34347378904     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070181     Document Type: Conference Paper

References (24)

1. Erslev AJ. Erythropoietin. N Engl J Med. 1991; 324:1339-44.
2. Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis. 1988; 11:238-47.
3. National Kidney Foundation. Kidney/Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 suppl 1):S1-266.
4. Thorp ML, Eastman L, Smith DH et al. Managing the burden of chronic kidney disease. Dis Manag. 2006; 9:115-21.
5. United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006. www.usrds.org/adr.htm. (accessed 2007 Feb 7).
6. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(5 suppl 3):S11-145.
7. Adamson JW. Iron deficiency and other hypoproliferative anemias. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2005:586-92.
8. Campbell D. How acute renal failure puts the brakes on kidney function. Nursing. 2003. 33:59-63.
9. Venkatesan J, Henrich WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Semin Nephrol. 1997; 17:257-69.
10. Levin A, Singer J, Thompson CR et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996; 27:347-54.
11. Muzzarelli S, Pfisterer M, TIME investigators. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J. 2006; 152:991-6.
12. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20:1501-10.
13. Anon. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group. Am J Kidney Dis. 1991; 18:50-9.
14. Provenzano R, Garcia-Mayol L, Suchinda P et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol. 2004; 61:392-405.
15. Lefebvre P, Vekeman F, Sarokhan B et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin. 2006; 22:1929-37.
16. Ayus JC, Go AS, Valderrabano F et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int. 2005; 68:788-95.
17. Jungers P, Choukroun G, Oualim Z et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001; 16:307-12.
18. Fink J, Blahut S, Reddy M et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis. 2001; 37:348-55.
19. Smith DH, Gullion CM, Nichols G et al. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol. 2004; 15:1300-6.
20. Besarab A. Optimizing anaemia management with subcutaneous administration of epoetin. Nephrol Dial Transplant. 2005; 20(suppl 6):vi10-5.
21. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40:439-46.
22. Hynes DM, Stroupe KT, Greer JW et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med. 2002; 112:169-75.
23. American Heart Association. Heart disease and stroke statistics: 2007 update at-a-glance. www.americanheart.org/downloadable/heart/ 1166711577754HS_StatsInsideText.pdf (accessed 2007 Feb 8).
24. Go AS, Yang J, Ackerson LM et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006; 113:2713-23.